Protocol
12-088
Full Title
A Phase 1 Study of IPI-145 in Patients with Advanced Hematologic Malignancies
Purpose
PI3 kinase is an enzyme that is overproduced by some cancers and can fuel cancer growth. PI3 kinase activity is known to be elevated in many hematologic cancers. IPI-145 is an investigational drug designed to inhibit cancer growth by blocking PI3 kinase activity.
In this study, researchers are determining the highest dose of IPI-145 that can be given safely in patients with advanced lymphoma, leukemia, or multiple myeloma that persists or has worsened despite standard therapy. IPI-145 is a capsule that is taken orally (by mouth).
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have any advanced hematologic cancer other than acute leukemia, chronic myelogenous leukemia in blast crisis, or intermediate or high-risk myelodysplastic syndrome.
- Patients’ cancers must persist or have worsened despite any number of prior therapies.
- Patients must have recovered from the side effects of prior therapies.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Steven M. Horwitz at 212-639-3045.
Disease(s)
Hematology: Multiple Myeloma
Leukemia
Lymphoma: Non-Hodgkin's Lymphoma
Locations
ClinicalTrials.gov
Related Diseases
